Physician profile
Deeba N Ali
NPI 1750590691
$1,655.11
in general payments reported to CMS, 2019-2025
20 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.21 · 2021: $273 · 2022: $64.35 · 2023: $316 · 2024: $431 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $209.45 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $206.58 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $186.25 | 2021-2024 | |
| Travere Therapeutics, INC. | $150.79 | 2023 | |
| Opko Pharmaceuticals, LLC | $147.32 | 2019-2024 | Rayaldee |
| Janssen Pharmaceuticals, INC | $117.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.60 | 2024 | Jardiance |
| Ardelyx, INC. | $93.14 | 2025 | Xphozah 30 Mg, Ibsrela |
| Aurinia Pharma U.S., INC. | $84.25 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $75.71 | 2024-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $57.82 | 2022-2025 | Farxiga |
| Novo Nordisk INC | $40.70 | 2025 | Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $37.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $28.47 | 2025 | |
| Ani Pharmaceuticals, INC. | $26.01 | 2024 | Purified Cortrophin Gel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $21.47 | 2024 | Acthar |
| Calliditas Therapeutics US INC. | $19.60 | 2023 | Tarpeyo |
| Recor Medical INC | $17.86 | 2025 | Paradise Ultrasound Renal Denervation System |
| Lilly USA, LLC | $17.50 | 2023 | Jardiance |
| Vifor Pharma, INC. | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deeba Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.